MA39767B1 - Solution aqueuse ophtalmique et méthode de traitement du syndrome de l'œil sec - Google Patents

Solution aqueuse ophtalmique et méthode de traitement du syndrome de l'œil sec

Info

Publication number
MA39767B1
MA39767B1 MA39767A MA39767A MA39767B1 MA 39767 B1 MA39767 B1 MA 39767B1 MA 39767 A MA39767 A MA 39767A MA 39767 A MA39767 A MA 39767A MA 39767 B1 MA39767 B1 MA 39767B1
Authority
MA
Morocco
Prior art keywords
dry eye
aqueous solution
eye syndrome
treatment method
ophthalmic aqueous
Prior art date
Application number
MA39767A
Other languages
English (en)
Other versions
MA39767A (fr
Inventor
Martin Prinz
Original Assignee
Croma Pharma Ges M B H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50693490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39767(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Croma Pharma Ges M B H filed Critical Croma Pharma Ges M B H
Publication of MA39767A publication Critical patent/MA39767A/fr
Publication of MA39767B1 publication Critical patent/MA39767B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/10—Bag-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14—Details; Accessories therefor
    • A61J1/1468—Containers characterised by specific material properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D65/00—Wrappers or flexible covers; Packaging materials of special type or form
    • B65D65/38—Packaging materials of special type or form
    • B65D65/40—Applications of laminates for particular packaging purposes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
    • B65D81/24—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
    • B65D81/26—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators
    • B65D81/266—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators for absorbing gases, e.g. oxygen absorbers or desiccants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mechanical Engineering (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

La présente invention concerne une solution aqueuse ophtalmique stérile comprenant d'environ 0,05 % à environ 0,5 % (poids/poids) de n-(n-acétylcystéinyl-)chitosane ou un sel pharmaceutiquement acceptable de celui-ci dans une solution d'excipient, le n-(n-acétylcystéinyl-)chitosane présentant une teneur en groupes thiol libres en proportion allant de 80 µmol/g de polymère à 280 µmol/g de polymère. L'invention concerne également un récipient contenant ladite solution ophtalmique ainsi que l'utilisation de celui-ci dans la prévention ou le traitement du syndrome de l'œil sec ou des signes et/ou des symptômes de l'œil sec.
MA39767A 2014-05-07 2015-05-04 Solution aqueuse ophtalmique et méthode de traitement du syndrome de l'œil sec MA39767B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14167381 2014-05-07
PCT/EP2015/059674 WO2015169728A1 (fr) 2014-05-07 2015-05-04 Solution aqueuse ophtalmique et méthode de traitement du syndrome de l'œil sec
EP15718956.4A EP3139903B1 (fr) 2014-05-07 2015-05-04 Solution ophtalmique aqueuse et procédé pour traiter le syndrome de l'oeil sec

Publications (2)

Publication Number Publication Date
MA39767A MA39767A (fr) 2015-11-12
MA39767B1 true MA39767B1 (fr) 2019-10-31

Family

ID=50693490

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39767A MA39767B1 (fr) 2014-05-07 2015-05-04 Solution aqueuse ophtalmique et méthode de traitement du syndrome de l'œil sec

Country Status (28)

Country Link
US (2) US10342759B2 (fr)
EP (1) EP3139903B1 (fr)
JP (1) JP6639480B2 (fr)
KR (1) KR102378391B1 (fr)
CN (1) CN106456536B (fr)
AR (1) AR100334A1 (fr)
AU (1) AU2015257874B2 (fr)
BR (1) BR112016024454B1 (fr)
CA (1) CA2947065C (fr)
CL (1) CL2016002815A1 (fr)
CY (1) CY1122122T1 (fr)
DK (1) DK3139903T3 (fr)
ES (1) ES2747808T3 (fr)
HR (1) HRP20191667T1 (fr)
HU (1) HUE046425T2 (fr)
IL (1) IL248804B (fr)
LT (1) LT3139903T (fr)
MA (1) MA39767B1 (fr)
ME (1) ME03505B (fr)
MX (1) MX377727B (fr)
PL (1) PL3139903T3 (fr)
PT (1) PT3139903T (fr)
RS (1) RS59383B1 (fr)
RU (1) RU2688935C2 (fr)
SG (1) SG11201608402WA (fr)
SI (1) SI3139903T1 (fr)
SM (1) SMT201900525T1 (fr)
WO (1) WO2015169728A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3140296T3 (en) 2014-05-07 2018-07-23 Bristol Myers Squibb Co PYRROLIDIN GPR40 MODULATORS FOR TREATMENT OF DISEASES SUCH AS DIABETES
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
FR3039765B1 (fr) * 2015-08-07 2018-08-24 Oreal Procede cosmetique de traitement des matieres keratiniques
WO2017055924A2 (fr) 2015-09-28 2017-04-06 M.G. Therapeutics Ltd. Agents contenant un thiol et un disulfure permettant d'augmenter la sécrétion lipidique des glandes de meibomius
CN108348455B (zh) * 2015-10-30 2021-04-09 克罗马药品股份有限公司 无菌水性眼用溶液的治疗用途
PL3368006T3 (pl) 2015-10-30 2020-06-01 Croma-Pharma Gesellschaft M.B.H. Zastosowanie terapeutyczne sterylnego wodnego roztworu oftalmicznego
US10391119B2 (en) * 2015-12-22 2019-08-27 Nof Corporation Lacrimal oily layer stabilizer and eye drops comprising same
WO2017178892A2 (fr) 2016-04-14 2017-10-19 M.G. Therapeutics Ltd. Compositions de disulfure de sélénium destinées à être utilisées dans le traitement du dysfonctionnement de la glande de meibomius
CN109862899A (zh) * 2016-06-16 2019-06-07 护眼国际有限责任公司 治疗干眼综合征及其他创伤性非角质化上皮表面的组合物和方法
ES2650981B2 (es) 2016-07-20 2018-05-04 Ocupharm Diagnostics, Sl Preparación y uso de un extracto de Artemia salina para tratar la superficie ocular
CA3104325C (fr) * 2016-10-19 2023-01-24 Alcon Inc. Copolymere hydrophile a groupes thiol pendants
AR110125A1 (es) * 2016-11-07 2019-02-27 Croma Pharma Ges M B H Compuestos poliméricos que liberan sulfuro de hidrógeno
ES2669446B1 (es) * 2016-11-24 2019-03-13 Saiz Manuel Munoz Producto oftálmico
CA3057569A1 (fr) * 2017-03-29 2018-10-04 Azura Ophthalmics Ltd. Agents permettant d'augmenter la secretion des glandes lipidique de meibomius
WO2018202783A1 (fr) 2017-05-03 2018-11-08 Croma-Pharma Gmbh Solution ophtalmique aqueuse stérile contenant du n-(n-acétylcystéinyl)-chitosane pour le traitement de troubles de la cornée non infectieux
SG11202007977RA (en) * 2018-02-28 2020-09-29 Santen Pharmaceutical Co Ltd Ophthalmic composition comprising diquafosol and cationic polymer
JP2020075918A (ja) * 2018-11-02 2020-05-21 千寿製薬株式会社 角膜上皮創傷治癒促進用の眼科用組成物
CN109793707B (zh) * 2019-01-30 2022-04-08 温州医科大学 一种透明质酸—n-乙酰半胱氨酸—壳聚糖滴眼液及其制备方法
CN118948676A (zh) 2019-08-18 2024-11-15 普米戴格有限公司 用于防晒化合物的组合物及其方法
JP6966667B2 (ja) * 2019-08-27 2021-11-17 参天製薬株式会社 ジクアホソルまたはその塩、およびポリビニルピロリドンを含有する水性眼科用組成物
WO2021101883A1 (fr) * 2019-11-18 2021-05-27 Pamel Gregory J Compositions contenant du chitosane et procédés associés
EP4087655A4 (fr) 2020-01-10 2024-02-21 Azura Ophthalmics Ltd Instructions pour composition et sensibilité
CN114848670B (zh) * 2022-05-26 2023-06-02 青岛博益特生物材料股份有限公司 一种滴眼液及其制备方法
WO2024151787A1 (fr) * 2023-01-11 2024-07-18 MAM Holdings of West Florida, L.L.C. Méthodes et compositions de traitement du syndrome de l'œil sec, de l'hyperosmolarité et d'autres affections oculaires
US20240330778A1 (en) * 2023-04-03 2024-10-03 Halliburton Energy Services, Inc. Borehole holdup prediction using machine learning and pulsed neutron logging tool data

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1258781B (it) 1992-01-16 1996-02-29 Zambon Spa Composizione farmaceutica oftalmica contenente n-acetilcisteina e polivinilalcol
FR2692582B1 (fr) 1992-06-18 1998-09-18 Flamel Tech Sa Nouveaux derives reticulables de collagene, leur procede d'obtention et leur application a la preparation de biomateriaux.
KR19980703582A (ko) * 1995-04-04 1998-11-05 가와구치 시게키 염산 프로카테롤 수용액 제제를 보지하는 패키지 및 염산 프로카테롤 수용액 제제
EP0938896A1 (fr) * 1998-01-15 1999-09-01 Novartis AG Compositions pharmaceutiques autoclavables contenant des agents de chelation
AT406054B (de) * 1998-11-04 2000-02-25 Andreas Bernkop-Schnuerch Verfahren zur verbesserung der mucoadhäsion von polymeren sowie deren herstellung und verwendung
JP2000302803A (ja) 1999-04-22 2000-10-31 Noevir Co Ltd アミノ酸及びペプチドにより遊離アミノ基が選択的に置換され、実質的に水酸基の置換のない部分脱アセチル化キチン・キトサン誘導体、及びその製造方法
ITRM20010438A1 (it) * 2001-07-23 2003-01-23 Farmigea Spa Preparato oftalmico a base di n-acetilcisteina per il trattamento della sindrome dell'occhio secco.
WO2008052037A2 (fr) * 2006-10-24 2008-05-02 Alcon Research, Ltd. Matériaux d'emballage pour les formulations contenant des dérivés de 2-pyrrolidone
EP2107913B1 (fr) * 2006-12-22 2012-02-15 Croma-Pharma Gesellschaft m.b.H. Utilisation de polysaccharides comprenant des fonctions thiol pour l'augmentation tissulaire
WO2008094659A2 (fr) 2007-01-31 2008-08-07 Allergan, Inc. Nouveaux biomatériaux pour l'administration de médicaments oculaires et leur procédé de production et d'utilisation
US9452592B2 (en) 2007-08-28 2016-09-27 Cryovac, Inc. Multilayer film having an active oxygen barrier layer with radiation enhanced active barrier properties
EP2296637B1 (fr) 2008-04-24 2014-04-02 Medtronic, Inc Composition protectrice contenant du chitosane
CA2721937C (fr) 2008-04-24 2016-07-12 Medtronic, Inc. Gel protecteur a base de chitosane et de polysaccharide oxyde
JP5711113B2 (ja) 2008-04-24 2015-04-30 メドトロニック，インコーポレイテッド チオール化キトサンゲル

Also Published As

Publication number Publication date
ME03505B (fr) 2020-04-20
RU2016143341A3 (fr) 2018-12-25
RU2016143341A (ru) 2018-06-07
US20190269613A1 (en) 2019-09-05
IL248804A0 (en) 2017-01-31
JP6639480B2 (ja) 2020-02-05
MX377727B (es) 2025-03-11
JP2017514916A (ja) 2017-06-08
RS59383B1 (sr) 2019-11-29
SG11201608402WA (en) 2016-11-29
IL248804B (en) 2020-05-31
BR112016024454B1 (pt) 2023-03-07
DK3139903T3 (da) 2019-09-09
HRP20191667T1 (hr) 2019-12-13
AU2015257874B2 (en) 2019-11-28
US10342759B2 (en) 2019-07-09
CY1122122T1 (el) 2020-11-25
US10653620B2 (en) 2020-05-19
CN106456536B (zh) 2020-05-12
EP3139903A1 (fr) 2017-03-15
WO2015169728A1 (fr) 2015-11-12
BR112016024454A2 (pt) 2017-08-15
HUE046425T2 (hu) 2020-02-28
SMT201900525T1 (it) 2019-11-13
PT3139903T (pt) 2019-10-24
KR102378391B1 (ko) 2022-03-24
BR112016024454A8 (pt) 2021-06-29
SI3139903T1 (sl) 2019-10-30
CA2947065C (fr) 2022-04-19
MA39767A (fr) 2015-11-12
MX2016013710A (es) 2017-03-31
AR100334A1 (es) 2016-09-28
PL3139903T3 (pl) 2019-12-31
US20170224614A1 (en) 2017-08-10
CL2016002815A1 (es) 2017-05-12
LT3139903T (lt) 2019-09-10
CN106456536A (zh) 2017-02-22
CA2947065A1 (fr) 2015-11-12
KR20170030471A (ko) 2017-03-17
ES2747808T3 (es) 2020-03-11
AU2015257874A1 (en) 2016-10-20
EP3139903B1 (fr) 2019-07-03
RU2688935C2 (ru) 2019-05-23

Similar Documents

Publication Publication Date Title
MA39767A (fr) Solution aqueuse ophtalmique et méthode de traitement du syndrome de l'oeil sec
EP4374851A3 (fr) Composition ophtalmique pour le traitement d'une maladie de l' il sec
MY166228A (en) Compositions comprising mixtures of semifluorinated alkanes
MA43113A (fr) Anticorps anti-htr a1 et méthodes d'utilisation de ceux-ci
EA201890111A1 (ru) Замещенные производные оксопиридина
MY198587A (en) Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
MA39359A1 (fr) Composés d'isoindolinone utilisés comme modulateurs de gpr119 pour le traitement du diabète, de l'obésité et de troubles associés
EA201692008A1 (ru) Замещенные сконденсированные гетероциклы в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных нарушений
EA201692031A1 (ru) Фармацевтическая композиция с активным действием в отношении хронических бактериальных инфекций
MX2016010173A (es) Metodos de tratamiento de enfermedad de alzheimer.
MA49947B1 (fr) Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes
EA201992175A1 (ru) Композиции и способы, включающие пробиотические молекулы
MA42016A1 (fr) Compositions pharmaceutiques contenant un antagoniste de l'intégrine alpha 4, utilisées pour le traitement d''affections inflammatoires oculaires
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
MA38369A1 (fr) Peptides et compositions pour le traitement d'une lesion de l'articulation
BR112021014566A2 (pt) Moduladores de gpr35
EA202091308A1 (ru) Модифицированный вакцинный штамм brucella для лечения бруцеллеза
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
EA202192183A1 (ru) Композиции, обладающие активностью удаления липофусцина из клеток сетчатки
EP4636078A3 (fr) Kit de préparation d'un agent de traitement de maladie, agent de traitement de maladie et procédé de préparation d'un agent de traitement de maladie
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
EA201892389A1 (ru) Офтальмологическая композиция, содержащая синергическую комбинацию гликогена и гиалуроновой кислоты или ее соли
MA40915B1 (fr) Composition pharmaceutique comprenant le bisoprolol et le périndopril
AR106493A1 (es) Uso terapéutico de una solución oftálmica acuosa estéril
WO2017205779A3 (fr) Compositions et méthodes de traitement des troubles liés à l'activité de l'inflammasome et à l'expression de l'il-1alpha